Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1

Streetwise Reports, Streetwise Reports
0 Comments| June 13, 2018

{{labelSign}}  Favorites
{{errorMessage}}

Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease.

Click to enlarge

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB), in a June 12 press release, announced "the initiation of producer cell line development for PMN310, its lead therapeutic antibody candidate for treatment of Alzheimer's disease." Selexis SA, called a "global leader in mammalian (suspension-adapted CHO-K1) cell line generation," has signed on to manufacture the therapeutic.

Phase 1 clinical trials for PMN310 are slated to begin in the second half of 2019, according to the announcement. The drug targets toxic oligomers, which ProMIS calls a "root cause" of Alzheimer's disease.

ProMIS President and CEO Dr. Elliot Goldstein stated the company had "recently completed successful affinity maturation of PMN310, which in addition to its unique and highly selective binding profile offers increased opportunity for best in class therapy for Alzheimer's disease."

Both Goldstein and Selexis vice president Yemi Onakunle highlighted the synergy between the two companies' products. "We believe our best-in-class technology can help propel forward this best-in-class therapeutic candidate," Onakunle stated in the release.



{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company